Lotus Eye Hospital And Institute Ltd · NSE:LOTUSEYE
Lotus Eye Hospital And Institute — Q4 FY2020-21 Earnings Presentation
26 slides from Lotus Eye Hospital And Institute's earnings presentation, Jul 3, 2021
Slide 1: Exchange filing cover letter
LOTUS Lotus Eye Hospital And Institute Limited TUV CIN No.: L85110TZ1997PLCO07783 SOD 770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore 641 014. 1s0980 Tel:0422-4229900,4229999 Fax:0422 4229933 METTUPPALAYAM TIRUPUR SALEM R.S. PURAM No. 28, Coimbatore Main Rd, No. 5(2) GajalakshmiTheatre Road
Slide 2: Investor Presentation Q4 (FY 2020-2021)
Investor Presentation Q4 (FY 2020-2021)
Slide 3: Thanks to our founder
Thanks to OUR FOUNDER Late Dr. S. K. SUNDARAMOORTHY (21.08.1944 - 22.01.2020) “There are some who bring a light so great to the world that even after they have gone the light remains” Our founder Dr. S.K. Sundaramoorthy was one of the acclaimed and famed eye surgeons of our country and worldwide. He
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Lotus Eye Hospital and Institute Limited (the “Company”) solely for your information and for your use and may not be, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person or published in whole or in part
Slide 5: Agenda
Agenda Overview Financial Performance Q4 Key Highlights 2020-21 At a Glance Strategy going forward
Slide 6: Company Overview
Company Overview Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy Lotus Eye Hospitals operates 7 Eye Care centers in Tamil Nadu and Kerala 5 Centres in Tamil Nadu: Coimbatore (Peelamedu & RS puram), Salem , Tirupur and Mettupalayam 2 Centres in Kerala: Kochi and Mu
Slide 7: Vision
Vision To become world’s leading eye care provider with happy and satisfied patients and stake holders. Lotus has a vision of "empowering eyes to illuminate lives". Lotus Eye Care group is marching towards its vision of becoming India's best Corporate Hospital with branches in strategic locations wh
Slide 8: Wide Range of Services
Wide Range of Services Refractive Ocuplasty Glaucoma LASIK/ BladelessLASIK Enucleation Trabeculectomy Zyoptix & Zyoptix Ultimate Evisceration Epizyoptix & Epizyoptix Ultimate DCR &DCT SMILE PTOSIS Paediatric refraction and Special Kertometer Lateral Tarsorrhaphy Synaptophore
Slide 9: Key Milestones
Key Milestones 2002 1992 1994 (1) New center: Sitra, 1st company to Coimbatore Inauguration of introduce Stitch-less (2) Introduced Wave Lotus Eye Phaco-emulsification front based Esiris Hospital and Cataract surgery in Custom Lasik for the 1st Research Centre Coimbatore time in India 1 3 5 C1 Start
Slide 10: Key Milestones
Key Milestones 2005 Introduced Zyoptix Z100; 2008 2010 combined 2 technologies New center: (Epilasik and Zyoptix), known Launch of IPO Mettupalayam as Epizyoptix 8 10 12 C1 C2 7 9 11 (1) Inauguration of Hospital in Salem, Tamil Nadu, Inauguration Launched Intralase (2) 1st company in SEA to Hospital
Slide 11: Key Milestones
Key Milestones 2011 (1) New center: Kochi, 2019 Kerala, 2014 (2) Introduced Zyoptix Launched Schwind Supracor for the 1st Amaris 750Hz Touch New center: time in Tamil Nadu, Free Lasik Technology Mulanthuruthy, Kerala (3) Introduced Zyoptix at RS Puram Ultimate 217P technology 13 15 17 C2 14 16 Intro
Slide 12: Management
Management “In this aeon for LOTUS, the importance, emphasis and priority, will always be in ensuring and securing the credence and credibility of our existing shareholders.” Ms. Sangeetha Sundaramoorthy Managing Director “The ambition and objectives is to actualize and institute an earnest, unrelen
Slide 13: Lotus Vision Research Trust
Lotus Vision Research Trust Vision Overview To prevent & eradicate blindness with dedication and • Established in 1993 humanitarian approach. • 200+Eye Camps conducted in single year • 120+ Free cataract surgery under DBCS Scheme • Runs Optometry Educational Institutions – 5000+ graduated in the pas
Slide 14: Agenda
Agenda Overview Financial Performance Q4 Key Highlights 2020-21 At a Glance Strategy going forward
Slide 15: Financial Performance (for Quarter ending 31.03.2021)
Financial Performance (for Quarter ending 31.03.2021) REVENUE (3 MONTHS) (in lakhs) 31-03-21 31-12-20 31-03-20 Revenue from operations 1056.70 987.34 816.84 Other Income 18.67 19.96 22.21 Total Income 1075.37 1007.29 839.05 EXPENSES (3 MONTHS) (in lakhs) 31-03-21 31-12-20 31-03-20 Cost of Material C
Slide 16: Financial Performance (for Year ending 31.03.2021)
Financial Performance (for Year ending 31.03.2021) REVENUE (in lakhs) 31-03-21 31-03-20 Revenue from operations 3236.90 4055.31 Other Income 74.25 90.02 Total Income 3311.15 4145.33 EXPENSES (in lakhs) 31-03-21 31-03-20 Cost of Material Consumed 508.83 568.07 Purchase of stock - in trade 476.02 610.
Slide 17: Agenda
Agenda Overview Financial Performance Q4 Key Highlights 2020-21 At a Glance Strategy going forward
Slide 18: Q4 Key Highlights
Q4 Key Highlights Our Managing Director Ms. Sangeetha Sundaramoorthy has been awarded as Mar’21 - All NEW time Best Budding Entrepreneur Healthcare 5000+ PATIENTS Business – Post COVID by Times Group Through EYE Corporate & 2800+ SCREENED Public Eye Camps in TN & KL Dr. K. S Ramalingam ADDITIONS 2 T
Slide 19: Agenda
Agenda Overview Financial Performance Q4 Key Highlights 2020-21 At a Glance Strategy going forward
Slide 20: 2020-21 Year at Glance
2020-21 Year at Glance New Management takes center stage Chairman MD CEO Dr. Kavetha Ms. Sangeetha Dr. K.S. Ramalingam Sundaramoorthy Sundaramoorthy Apptd. as MD w.e.f 24-09-2020 Apptd. as CEO w.e.f 05-08-2020 Apptd. as Chairman w.e.f 11-11-2020 Apptd. as Ex.Dir w.e.f 09-02-2021
Slide 21: 2020-21 Year at Glance
2020-21 Year at Glance Share price of Lotus 5% Dividend approved by Board* reached All-Time-High *Subject to approval of Shareholders at ensured A.G.M Market Capitalization crosses First time Brand promotions done via 100Cr. for the first time. National Television (Star Vijay) Lotus Salem ranked as
Slide 22: Agenda
Agenda Overview Financial Performance Q4 Key Highlights 2020-21 At a Glance Strategy going forward
Slide 23: SWOT Analysis
SWOT Analysis INTERNAL STRENGTHS WEAKNESSES • Prominent Technology • Single Specialty • Leading Doctors • Presence only in South-India • Staunch and Robust Management • Steady Financials OPPORTUNITIES THREATS EXTERNAL • Opportunities in Adjacent Markets • Current Pandemic Situation • Medical technol
Slide 24: Strategy Going Forward
Strategy Going Forward >> To magnify and propel To be conservative of To have a wider & To build on expanded To shape the workforce for existing strengths contingencies & yet be augmented digital technical know-how the future outward looking at the presence same time
Slide 25: Acumen of LOTUS
Lotus has gone from strength to strength, since its inception and the results impersonate the same intension and emotions. The year was marked with challenges and hardships in more than one ways, but it was the sheer Acumen of LOTUS C determination and resolve of the management to successfully overc
Slide 26: Thanks! Any questions?
Thanks! Any questions? You can reach us at: companysecretary@lotuseye.org
Lotus Eye Hospital and Institute — Q4 FY2020-21 Earnings Presentation on 6ix